Allogeneic Hematopoietic Stem Cell Transplantation
Conditions
Interventions
Case series:No
Sponsors
The First Affiliated Hospital of Soochow University
Eligibility
Sex/Gender
All
Age
15 Years to 70 Years
Inclusion criteria
Inclusion criteria: Subjects suitable for inclusion in this study must meet all of the following criteria: 1. Recipients of allogeneic hematopoietic stem cell transplantation (including HLA matched or incomplete matched allogeneic hematopoietic stem cell transplantation and unrelated donor transplantation); 2. Aged >= 15 years and < 70 years, male or female; 3. The ECOG-ps score of Eastern oncology cooperation group is 0-2; 4. The informed consent form must be signed before the start of the research procedure. For those aged 18 or above, the informed consent form shall be signed by the patient himself or his immediate family members; The legal guardian shall sign the informed consent form for children and adolescents under 18 years old. Considering the patient's condition, if the patient's signature is not conducive to the treatment of the condition, the legal guardian or the patient's immediate family member shall sign the informed consent form.
Exclusion criteria
Exclusion criteria: Subjects who meet any of the following criteria shall not be selected for this study: 1. Pulmonary and digestive tract active infection was identified before transplantation; 2. The serological reaction of HIV or active hepatitis C virus is known to be positive; 3. Suffering from mental illness or other diseases and unable to cooperate with the requirements of research treatment and monitoring; 4. Pregnant patients or patients who cannot take appropriate contraceptive measures during treatment; 5. Received hematopoietic stem cell transplantation in the past year; 6. Active heart disease is defined as one or more of the following: (1) History of uncontrolled or symptomatic angina pectoris; (2) Myocardial infarction less than 6 months before the study; (3) A history of arrhythmia requiring medication or with severe clinical symptoms; (4) Uncontrolled or symptomatic congestive heart failure (> NYHA grade 2); (5) The ejection fraction was lower than the lower limit of the normal range; (6) Patients who refused to be enrolled in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| oropharyngeal swab sequencing;Blood culture sequencing;oropharyngeal swab culture;Blood culture; | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival;aGVHD;EBV infection;CMV infection;Oral and oropharyngeal mucositis; | — |
Countries
China
Contacts
Public ContactJisheng Liu; Depei Wu
The First Affiliated Hospital of Soochow University
Outcome results
None listed